Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and Gilead Sciences have entered a licensing agreement for the development and commercialization of a new fixed-dose combination pill for HIV infected patients.
Subscribe to our email newsletter
The combination contains Bristol-Myers Squibb’s protease inhibitor Reyataz (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing agent which increases blood levels of certain HIV medicines to enable a dosing of one pill per day.
Reyataz is a prescription medicine used in combination with other medicines to treat HIV infected patients who are 6 years of age or older.
In accordance with the deal, Bristol-Myers Squibb will pay Gilead an undisclosed royalty based on annual net sales of the product.
Gilead on the other hand retains exclusive rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.